Review Article
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
Figure 2
Meta-analysis of the efficacy of MAb group and HDACi group in patients with RRMM: (a) hazard ratio for progression free survival of MAb group and HDACi group versus their corresponding control group; (b) hazard ratio for overall survival of MAb group and HDACi group versus their corresponding control group; and (c) hazard ratio for progression-free survival of daratumumab group and HDACi group versus their corresponding control group. āā in Figure 2(a) and Figure 2(c), which was automatically generated by Stata software, represents actually, denoting that there exists heterogeneity among studies.
(a) |
(b) |
(c) |